Skip to main content
Press release November 9, 2026

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience, Inc. (NAGE)

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: A.G.P. Virtual Consumer Showcase Virtual showcase offering consumer company management teams a platform to share their story with the investment community Location: Virtual Date: November 11 - 12, 2026 Format: Fireside chat Thursday, November 12, 2026 at 3:00 p.m. ET Management: Rob Fried, CEO & Ozan Pamir, CFO Investors may register here Southwest IDEAS Investor Conference Independent institutional investor conference for publicly traded companies and institutional investors Location: The Westin Irving Convention Center in Las Colinas, Irving, Texas Date: November 18 - 19, 2026 Format: Presentation on Thursday, November 19, 2026 from 4:00 - 4:35 p.m. CT and one-on-one meetings Management: Rob Fried, CEO & Ozan Pamir, CFO 15th Annual ROTH Deer Valley Event Invite-only annual networking conference for institutional investors and select public/private company management teams. Location: Montage Deer Valley Park City, Utah Date: December 9 - 12, 2026 Format: One-on-one meetings Management: Rob Fried, CEO StoneX 15th Annual Discovery Conference 2026 Emerging growth investor forum for institutional investors and select public and private emerging growth companies. Location: New York Athletic Club New York, New York Date: December 10, 2026 Format: One-on-one meetings Management: Ozan Pamir, CFO If you would like to schedule a one-on-one meeting with the Niagen management team during either conference, please contact your respective conference representative or email Niagen@KCSA.com. For additional information on Niagen Bioscience, visit www.niagenbioscience.com. About Niagen Bioscience Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age. At the heart of its clinically tested product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen ® , the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule. Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published. † Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025) Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310.405.5227 kendall.knysch@niagenbio.com Niagen Bioscience Investor Relations Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 Niagen@kcsa.com Source: Niagen Bioscience, Inc
View original release